{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,5]],"date-time":"2026-08-05T07:08:56Z","timestamp":1785913736236,"version":"3.56.0"},"reference-count":39,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2025,5,23]],"date-time":"2025-05-23T00:00:00Z","timestamp":1747958400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2025,5,23]],"date-time":"2025-05-23T00:00:00Z","timestamp":1747958400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ophthalmol Ther"],"published-print":{"date-parts":[[2025,7]]},"DOI":"10.1007\/s40123-025-01149-4","type":"journal-article","created":{"date-parts":[[2025,5,23]],"date-time":"2025-05-23T14:57:35Z","timestamp":1748012255000},"page":"1533-1549","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Pooled Analysis of Three MicroShunt Studies in Primary Open-Angle Glaucoma Evaluating Different Concentrations of Applied Mitomycin C"],"prefix":"10.1007","volume":"14","author":[{"given":"Juli\u00e1n","family":"Garcia-Feijoo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan F.","family":"Batlle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Florent","family":"Aptel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yves","family":"Lachkar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isabelle","family":"Riss","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Omar","family":"Sadruddin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tuan","family":"Nguyen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Henny J. M.","family":"Beckers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,5,23]]},"reference":[{"key":"1149_CR1","doi-asserted-by":"publisher","first-page":"262","DOI":"10.1136\/bjo.2005.081224","volume":"90","author":"HA Quigley","year":"2006","unstructured":"Quigley HA, Broman AT. The number of people with glaucoma worldwide in 2010 and 2020. Br J Ophthalmol. 2006;90:262\u20137.","journal-title":"Br J Ophthalmol"},{"key":"1149_CR2","doi-asserted-by":"publisher","first-page":"e1221","DOI":"10.1016\/S2214-109X(17)30393-5","volume":"5","author":"SR Flaxman","year":"2017","unstructured":"Flaxman SR, Bourne RRA, Resnikoff S, Vision Loss Expert Group of the Global Burden of Disease Study, et al. Global causes of blindness and distance vision impairment 1990\u20132020: a systematic review and meta-analysis. Lancet Glob Health. 2017;5:e1221\u201334.","journal-title":"Lancet Glob Health"},{"key":"1149_CR3","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1016\/j.pop.2015.05.008","volume":"42","author":"AV Mantravadi","year":"2015","unstructured":"Mantravadi AV, Vadhar N. Glaucoma. Prim Care. 2015;42:437\u201349.","journal-title":"Prim Care"},{"key":"1149_CR4","doi-asserted-by":"publisher","first-page":"P71","DOI":"10.1016\/j.ophtha.2020.10.022","volume":"128","author":"SJ Gedde","year":"2021","unstructured":"Gedde SJ, Vinod K, Wright MM, American Academy of Ophthalmology Preferred Practice Pattern Glaucoma Panel, et al. Primary open-angle glaucoma preferred practice pattern. Ophthalmology. 2021;128:P71-150.","journal-title":"Ophthalmology"},{"key":"1149_CR5","doi-asserted-by":"crossref","unstructured":"European Glaucoma Society terminology and guidelines for glaucoma, 4th edition\u2014chapter 3: treatment principles and options supported by the EGS Foundation: part 1: foreword; introduction; glossary; Chapter 3 treatment principles and options. Br J Ophthalmol. 2017; 101:130\u201395.","DOI":"10.1136\/bjophthalmol-2016-EGSguideline.003"},{"key":"1149_CR6","doi-asserted-by":"publisher","first-page":"1505","DOI":"10.1016\/S0140-6736(18)32213-X","volume":"393","author":"G Gazzard","year":"2019","unstructured":"Gazzard G, Konstantakopoulou E, Garway-Heath D, LiGHT Trial Study Group, et al. Selective laser trabeculoplasty versus eye drops for first-line treatment of ocular hypertension and glaucoma (LiGHT): a multicentre randomised controlled trial. Lancet. 2019;393:1505\u201316.","journal-title":"Lancet"},{"key":"1149_CR7","doi-asserted-by":"publisher","first-page":"467","DOI":"10.1016\/j.ophtha.2019.10.023","volume":"127","author":"A Garg","year":"2020","unstructured":"Garg A, Vickerstaff V, Nathwani N, et al. Efficacy of repeat selective laser trabeculoplasty in medication-naive open-angle glaucoma and ocular hypertension during the LiGHT trial. Ophthalmology. 2020;127:467\u201376.","journal-title":"Ophthalmology"},{"key":"1149_CR8","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1159\/000334776","volume":"50","author":"PT Khaw","year":"2012","unstructured":"Khaw PT, Chiang M, Shah P, Sii F, Lockwood A, Khalili A. Enhanced trabeculectomy: the Moorfields Safer Surgery System. Dev Ophthalmol. 2012;50:1\u201328.","journal-title":"Dev Ophthalmol"},{"key":"1149_CR9","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0183142","volume":"12","author":"C Lavia","year":"2017","unstructured":"Lavia C, Dallorto L, Maule M, Ceccarelli M, Fea AM. Minimally-invasive glaucoma surgeries (MIGS) for open-angle glaucoma: a systematic review and meta-analysis. PLoS ONE. 2017;12: e0183142.","journal-title":"PLoS ONE"},{"key":"1149_CR10","doi-asserted-by":"publisher","first-page":"12850","DOI":"10.1038\/s41598-024-61811-y","volume":"14","author":"J Konopinska","year":"2024","unstructured":"Konopinska J, Golaszewska K, Saeed E. Minimally invasive bleb surgery versus minimally invasive glaucoma surgery: a 12-month retrospective study. Sci Rep. 2024;14:12850.","journal-title":"Sci Rep"},{"key":"1149_CR11","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1167\/tvst.8.3.58","volume":"8","author":"RMH Lee","year":"2019","unstructured":"Lee RMH, Bouremel Y, Eames I, Brocchini S, Khaw PT. The implications of an ab interno versus ab externo surgical approach on outflow resistance of a subconjunctival drainage device for intraocular pressure control. Transl Vis Sci Technol. 2019;8:58.","journal-title":"Transl Vis Sci Technol"},{"key":"1149_CR12","doi-asserted-by":"publisher","first-page":"e58","DOI":"10.1097\/IJG.0000000000000368","volume":"25","author":"JF Batlle","year":"2016","unstructured":"Batlle JF, Fantes F, Riss I, et al. Three-year follow-up of a novel aqueous humor MicroShunt. J Glaucoma. 2016;25:e58-65.","journal-title":"J Glaucoma"},{"key":"1149_CR13","doi-asserted-by":"publisher","first-page":"1742","DOI":"10.1001\/archopht.124.12.1742","volume":"124","author":"AC Acosta","year":"2006","unstructured":"Acosta AC, Espana EM, Yamamoto H, et al. A newly designed glaucoma drainage implant made of poly(styrene-b-isobutylene-b-styrene): biocompatibility and function in normal rabbit eyes. Arch Ophthalmol. 2006;124:1742\u20139.","journal-title":"Arch Ophthalmol"},{"key":"1149_CR14","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1093\/rb\/rbw005","volume":"3","author":"L Pinchuk","year":"2016","unstructured":"Pinchuk L, Riss I, Batlle JF, et al. The use of poly(styrene-block-isobutylene-block-styrene) as a MicroShunt to treat glaucoma. Regen Biomater. 2016;3:137\u201342.","journal-title":"Regen Biomater"},{"key":"1149_CR15","unstructured":"US National Library of Medicine. Safety and performance of Miami InnFocus Drainage Implant (MIDI Arrow) glaucoma drainage implant. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT01563237. Accessed 12 Feb 2022."},{"key":"1149_CR16","unstructured":"US National Library of Medicine. Clinical study of the safety and performance of the Miami InnFocus Drainage Implant to relieve glaucoma symptoms. ClinicalTrials.gov Identifier: NCT00772330]. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT00772330. Accessed 12 Feb 2022."},{"key":"1149_CR17","unstructured":"US National Library of Medicine. Post market study of the InnFocus MicroShunt. ClinicalTrials.gov Identifier: NCT02177123. https:\/\/www.clinicaltrials.gov\/ct2\/show\/NCT02177123. Accessed 12 Feb 2022."},{"key":"1149_CR18","unstructured":"Santen Canada Inc. Santen announces Health Canada approval of PRESERFLO\u2122 MicroShunt. https:\/\/www.santen.com\/content\/dam\/santen\/us\/pdf\/News\/2021\/preserflo-microshunt-canada-approval.pdf. Accessed 12 Feb 2022."},{"key":"1149_CR19","unstructured":"Santen Pharmaceutical Co., Ltd. Santen receives marketing approval in Japan for \u201cPRESERFLO MicroShunt Glaucoma Drainage System Core Kit\u201d to treat glaucoma. https:\/\/www.santen.com\/content\/dam\/santen\/global\/pdf\/en\/news\/20220228.pdf; Accessed 12 Feb 2022."},{"key":"1149_CR20","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1097\/IJG.0000000000001734","volume":"30","author":"JF Batlle","year":"2021","unstructured":"Batlle JF, Corona A, Albuquerque R. Long-term results of the PRESERFLO MicroShunt in patients with primary open-angle glaucoma from a single-center nonrandomized study. J Glaucoma. 2021;30:281\u20136.","journal-title":"J Glaucoma"},{"key":"1149_CR21","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1016\/j.ogla.2021.07.008","volume":"5","author":"HJM Beckers","year":"2022","unstructured":"Beckers HJM, Aptel F, Webers CAB, et al. Safety and effectiveness of the PRESERFLO MicroShunt in primary open-angle glaucoma: results from a 2-year multicenter study. Ophthalmol Glaucoma. 2022;5:195\u2013209.","journal-title":"Ophthalmol Glaucoma"},{"key":"1149_CR22","doi-asserted-by":"publisher","first-page":"206","DOI":"10.1159\/000526960","volume":"66","author":"I Riss","year":"2023","unstructured":"Riss I. A 2-year, single-center study to assess the safety and effectiveness of the MicroShunt in primary open-angle glaucoma. Ophthalmic Res. 2023;66:206\u201317.","journal-title":"Ophthalmic Res"},{"key":"1149_CR23","doi-asserted-by":"publisher","first-page":"112","DOI":"10.4103\/0974-9233.56220","volume":"16","author":"S Dhingra","year":"2009","unstructured":"Dhingra S, Khaw PT. The Moorfields Safer Surgery System. Middle East Afr J Ophthalmol. 2009;16:112\u20135.","journal-title":"Middle East Afr J Ophthalmol"},{"key":"1149_CR24","doi-asserted-by":"publisher","first-page":"1213","DOI":"10.1016\/S0161-6420(98)97023-3","volume":"105","author":"DA Schaumberg","year":"1998","unstructured":"Schaumberg DA, Dana MR, Christen WG, Glynn RJ. A systematic overview of the incidence of posterior capsule opacification. Ophthalmology. 1998;105:1213\u201321.","journal-title":"Ophthalmology"},{"key":"1149_CR25","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1016\/S0161-6420(00)00589-3","volume":"108","author":"DJ Apple","year":"2001","unstructured":"Apple DJ, Peng Q, Visessook N, et al. Eradication of posterior capsule opacification: documentation of a marked decrease in Nd:YAG laser posterior capsulotomy rates noted in an analysis of 5416 pseudophakic human eyes obtained postmortem. Ophthalmology. 2001;108:505\u201318.","journal-title":"Ophthalmology"},{"key":"1149_CR26","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1016\/j.ajo.2020.02.020","volume":"215","author":"MB Schlenker","year":"2020","unstructured":"Schlenker MB, Durr GM, Michaelov E, Ahmed IIK. Intermediate outcomes of a novel standalone ab externo SIBS MicroShunt with mitomycin C. Am J Ophthalmol. 2020;215:141\u201353.","journal-title":"Am J Ophthalmol"},{"key":"1149_CR27","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1097\/00061198-199906000-00008","volume":"8","author":"SP Sanders","year":"1999","unstructured":"Sanders SP, Cantor LB, Dobler AA, Hoop JS. Mitomycin C in higher risk trabeculectomy: a prospective comparison of 0.2- to 0.4-mg\/cc doses. J Glaucoma. 1999;8:193\u20138.","journal-title":"J Glaucoma"},{"key":"1149_CR28","doi-asserted-by":"publisher","first-page":"59","DOI":"10.3390\/jcm10010059","volume":"10","author":"BR Seol","year":"2020","unstructured":"Seol BR, Lee SY, Kim YJ, Kim YK, Jeoung JW, Park KH. Comparison of the efficacy and safety of trabeculectomy with mitomycin C according to concentration: a prospective randomized clinical trial. J Clin Med. 2020;10:59.","journal-title":"J Clin Med"},{"key":"1149_CR29","first-page":"CD002897","volume":"2005","author":"M Wilkins","year":"2005","unstructured":"Wilkins M, Indar A, Wormald R. Intra-operative mitomycin C for glaucoma surgery. Cochrane Database Syst Rev. 2005;2005:CD002897.","journal-title":"Cochrane Database Syst Rev"},{"key":"1149_CR30","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1016\/j.ajo.2012.09.011","volume":"155","author":"S Zahid","year":"2013","unstructured":"Zahid S, Jayasundera T, Rhoades W, et al. Clinical phenotypes and prognostic full-field electroretinographic findings in Stargardt disease. Am J Ophthalmol. 2013;155:465-73.e3.","journal-title":"Am J Ophthalmol"},{"key":"1149_CR31","doi-asserted-by":"publisher","first-page":"1710","DOI":"10.1016\/j.ophtha.2021.05.023","volume":"128","author":"ND Baker","year":"2021","unstructured":"Baker ND, Barnebey HS, Moster MR, INN005 Study Group, et al. Ab-externo MicroShunt versus trabeculectomy in primary open-angle glaucoma: one-year results from a 2-year randomized, multicenter study. Ophthalmology. 2021;128:1710\u201321.","journal-title":"Ophthalmology"},{"key":"1149_CR32","doi-asserted-by":"publisher","first-page":"266","DOI":"10.1016\/j.ophtha.2023.09.023","volume":"131","author":"JF Panarelli","year":"2024","unstructured":"Panarelli JF, Moster MR, Garcia-Feijoo J, INN005 Study Group, et al. Ab-externo MicroShunt versus trabeculectomy in primary open-angle glaucoma: two-year results from a randomized, multicenter study. Ophthalmology. 2024;131:266\u201376.","journal-title":"Ophthalmology"},{"key":"1149_CR33","doi-asserted-by":"publisher","first-page":"968","DOI":"10.1038\/s41433-023-02816-1","volume":"38","author":"D Maheshwari","year":"2024","unstructured":"Maheshwari D, Pillai MR, Hm P, Ramakrishnan R, Kader MA, Pawar N. Long-term outcomes of mitomycin-C augmented trabeculectomy using subconjunctival injections versus soaked sponges: a randomised controlled trial. Eye (Lond). 2024;38:968\u201372.","journal-title":"Eye (Lond)"},{"key":"1149_CR34","doi-asserted-by":"publisher","first-page":"1196","DOI":"10.1038\/s41433-023-02869-2","volume":"38","author":"S Chakrabarty","year":"2024","unstructured":"Chakrabarty S, Kader MA, Maheshwari D, Pillai MR, Chandrashekharan S, Ramakrishnan R. Short-term outcomes of mitomycin-C augmented phaco-trabeculectomy using subconjunctival injections versus soaked sponges: a randomized controlled trial. Eye (Lond). 2024;38:1196\u2013201.","journal-title":"Eye (Lond)"},{"key":"1149_CR35","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1016\/j.ajo.2020.07.002","volume":"220","author":"JL Do","year":"2020","unstructured":"Do JL, Xu BY, Wong B, et al. A randomized controlled trial comparing subconjunctival injection to direct scleral application of mitomycin C in trabeculectomy. Am J Ophthalmol. 2020;220:45\u201352.","journal-title":"Am J Ophthalmol"},{"key":"1149_CR36","doi-asserted-by":"publisher","DOI":"10.1177\/11206721241266981","author":"D Maheshwari","year":"2024","unstructured":"Maheshwari D, Pillai MR, Hm P, Kader MA, Rengappa R, Pawar N. Long-term safety and efficacy of injection mitomycin C (MMC) versus sponge application in trabeculectomies. Eur J Ophthalmol. 2024. https:\/\/doi.org\/10.1177\/11206721241266981. (in press).","journal-title":"Eur J Ophthalmol"},{"key":"1149_CR37","doi-asserted-by":"publisher","first-page":"253","DOI":"10.4103\/joco.joco_57_20","volume":"33","author":"W Chiew","year":"2021","unstructured":"Chiew W, Guo X, Ang BCH, Lim APH, Yip LWL. Comparison of surgical outcomes of sponge application versus subconjunctival injection of mitomycin-C during combined phacoemulsification and trabeculectomy surgery in Asian eyes. J Curr Ophthalmol. 2021;33:253\u20139.","journal-title":"J Curr Ophthalmol"},{"key":"1149_CR38","doi-asserted-by":"crossref","first-page":"402","DOI":"10.4103\/IJO.IJO_1080_24","volume":"72","author":"N Agarwal","year":"2024","unstructured":"Agarwal N, Krishna TS, Simha RA, Braganza AD, Gowri M, Abraham LM. Comparison of the safety and efficacy of mitomycin C 0.02% used intra-operatively by subconjunctival injection versus direct scleral application using sponges in phacotrabeculectomy: a prospective randomized controlled trial. Indian J Ophthalmol. 2024;72:402\u20137.","journal-title":"Indian J Ophthalmol"},{"key":"1149_CR39","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1097\/ICU.0000000000000729","volume":"32","author":"JEJ Wolters","year":"2021","unstructured":"Wolters JEJ, van Mechelen RJS, Al Majidi R, et al. History, presence, and future of mitomycin C in glaucoma filtration surgery. Curr Opin Ophthalmol. 2021;32:148\u201359.","journal-title":"Curr Opin Ophthalmol"}],"container-title":["Ophthalmology and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40123-025-01149-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40123-025-01149-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40123-025-01149-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,14]],"date-time":"2025-06-14T07:49:52Z","timestamp":1749887392000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40123-025-01149-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,23]]},"references-count":39,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2025,7]]}},"alternative-id":["1149"],"URL":"https:\/\/doi.org\/10.1007\/s40123-025-01149-4","relation":{},"ISSN":["2193-8245","2193-6528"],"issn-type":[{"value":"2193-8245","type":"print"},{"value":"2193-6528","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,5,23]]},"assertion":[{"value":"15 November 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 April 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 May 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Julian Garcia-Feijoo: Consultant\u2014Alcon, AbbVie, Glaukos, iSTAR, Santen; Thea; Sight Science; Alimera; Elios Vision; Financial support\u2014Alcon, AbbVie, iSTAR, Novartis, Th\u00e9a, Glaukos, Pfizer, Santen, Elios, ZEISS; Heidelberg; AJL; J&J; B&L; Thea; Sight Science; Rayner; Cutting Edge; Physiol; Biotech and Pfizer. Juan F. Batlle: Consultant\u2014Santen Inc., Aquea Health, W.L. Gore & Associates, Inc.; Paid speaker\u2014Johnson & Johnson Vision; Research support\u2014CORD LLC, InnFocus Inc. (a Santen Pharmaceutical Co Ltd Company), Johnson & Johnson Vision, LensGen Inc., New World Medical Inc., Omega Ophthalmics, Inc., TECLens LLC; Investment interest: Aquea Health, CORD LLC, LensGen Inc. Florent Aptel: Consultant\u2014Allergan, Glaukos, Novartis, Santen, Th\u00e9a. Yves Lachkar: Consultant for Allergan, Novartis, Santen, Th\u00e9a. Isabelle Riss: Consultant\u2014Santen; Research support\u2014Santen. Omar Sadruddin: is an employee of Glaukos. Tuan Nguyen: is an employee of Edwards Lifesciences. Henny J.M. Beckers: Consultant\u2014InnFocus Inc. (a Santen Pharmaceutical Co. Ltd. company), Santen, Glaukos, AbbVie, Novartis, Th\u00e9a, Elios, Nova Eye Medical; Research support\u2014InnFocus Inc. (a Santen Pharmaceutical Co. Ltd. company); Investment interest: Peyeoneer Medtech B.V.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"The individual studies were conducted in line with the principles of the Declaration of Helsinki and the following medical device standards: CFR 21 (INN003 only), MEDDEV 2.12-1 and MEDDEV 2.12\/2 revision 2 (INN007 only), MEDDEV 2.7\/1 and the European Directive 93\/42\/EEC (INN004 and INN007 only), and EN ISO 14155 (INN003, INN004, and INN007). Each study site obtained institutional review board approval. Informed consent was gained from all patients prior to enrollment in the individual studies.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}}]}}